Pfizer: Hyperlipidemias trials

The registry lists 27 Hyperlipidemias studies with Pfizer as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 9Phase 2 1Phase 3 17(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)CompletedNCT04516291Phase 2Results posted
• Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or DyslipidemiaCompletedNCT02458287Phase 3Results posted
• Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to StatinsCompletedNCT02135029Phase 3Results posted
• Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular EventsCompletedNCT02100514Phase 3Results posted
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk SubjectsTerminatedNCT01975389Phase 3Results posted
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk SubjectsTerminatedNCT01975376Phase 3Results posted
• Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsCompletedNCT01968967Phase 3Results posted
• Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular EventsCompletedNCT01968954Phase 3Results posted
• A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With HypercholesterolemiaCompletedNCT01435382Phase 1Results posted
• Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia SubjectsWithdrawnNCT02947334Phase 3
• A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy SubjectsCompletedNCT02855177Phase 1
• Single Dose Study of PF-06815345 in Healthy SubjectsTerminatedNCT02654899Phase 1
• A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography ScanningCompletedNCT02410525Phase 1
• A Multiple Oral Doses Study Of PF-06427878 In Healthy Adult SubjectsCompletedNCT02391623Phase 1
• A Single Oral Dose Study Of PF-06427878 In Healthy Adult SubjectsCompletedNCT02208284Phase 1
• A Multiple Dose Study Of PF-06678552 In Healthy SubjectsCompletedNCT02079922Phase 1
• A Single Dose Study Of PF-06678552 In Healthy SubjectsCompletedNCT01992614Phase 1
• A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult SubjectsCompletedNCT00991159Phase 1
• A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).TerminatedNCT00267280Phase 3
• A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.TerminatedNCT00267267Phase 3
• A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.CompletedNCT00267254Phase 3
• Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. FenofibrateCompletedNCT00139061Phase 3
• A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High CholesterolCompletedNCT00138762Phase 3
• Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.CompletedNCT00137462Phase 3
• Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.CompletedNCT00136981Phase 3
• Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial HypercholerolemiaCompletedNCT00134485Phase 3
• A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart DiseaseCompletedNCT00134173Phase 3